214 related articles for article (PubMed ID: 33130898)
21. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
[TBL] [Abstract][Full Text] [Related]
22. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
23. Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP
Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215
[TBL] [Abstract][Full Text] [Related]
24. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
25. Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDH
Wang S; Li L; Zuo S; Kong L; Wei J; Dong J
Front Immunol; 2022; 13():869061. PubMed ID: 36248907
[TBL] [Abstract][Full Text] [Related]
26. Predictors of Survival in Turkish Patients with Primary Glioblastoma.
Bilgin E; Duman BB; Altintas S; Cil T; Gezercan Y; Okten AI
Turk Neurosurg; 2021; 31(4):641-653. PubMed ID: 33759174
[TBL] [Abstract][Full Text] [Related]
27. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C
Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139
[TBL] [Abstract][Full Text] [Related]
29. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma.
Sun Z; Zhao Y; Wei Y; Ding X; Tan C; Wang C
Front Immunol; 2022; 13():939523. PubMed ID: 36091049
[TBL] [Abstract][Full Text] [Related]
30. Integrated molecular characterization of IDH-mutant glioblastomas.
Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
[TBL] [Abstract][Full Text] [Related]
31. Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.
Wee CW; Kim IH; Park CK; Kim JW; Dho YS; Ohka F; Aoki K; Motomura K; Natsume A; Kim N; Suh CO; Chang JH; Kim SH; Cho WK; Lim DH; Nam DH; Choi JW; Kim IA; Kim CY; Oh YT; Cho O; Chung WK; Kim SH; Kim E
Radiother Oncol; 2018 Nov; 129(2):347-351. PubMed ID: 30236994
[TBL] [Abstract][Full Text] [Related]
32. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.
Lötsch D; Ghanim B; Laaber M; Wurm G; Weis S; Lenz S; Webersinke G; Pichler J; Berger W; Spiegl-Kreinecker S
Neuro Oncol; 2013 Apr; 15(4):423-32. PubMed ID: 23393205
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients.
Ricklefs FL; Drexler R; Wollmann K; Eckhardt A; Heiland DH; Sauvigny T; Maire C; Lamszus K; Westphal M; Schüller U; Dührsen L
Neuro Oncol; 2022 Nov; 24(11):1886-1897. PubMed ID: 35511473
[TBL] [Abstract][Full Text] [Related]
35. Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
Oh S; Yeom J; Cho HJ; Kim JH; Yoon SJ; Kim H; Sa JK; Ju S; Lee H; Oh MJ; Lee W; Kwon Y; Li H; Choi S; Han JH; Chang JH; Choi E; Kim J; Her NG; Kim SH; Kang SG; Paek E; Nam DH; Lee C; Kim HS
Nat Commun; 2020 Jul; 11(1):3288. PubMed ID: 32620753
[TBL] [Abstract][Full Text] [Related]
36. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
38. MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas.
Mikkelsen VE; Dai HY; Stensjøen AL; Berntsen EM; Salvesen Ø; Solheim O; Torp SH
J Neuropathol Exp Neurol; 2020 Aug; 79(8):855-862. PubMed ID: 32688383
[TBL] [Abstract][Full Text] [Related]
39. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
[TBL] [Abstract][Full Text] [Related]
40. Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort.
Fukai J; Arita H; Umehara T; Yoshioka E; Shofuda T; Kanematsu D; Kodama Y; Mano M; Kinoshita M; Okita Y; Nonaka M; Uda T; Tsuyuguchi N; Sakamoto D; Uematsu Y; Nakao N; Mori K; Kanemura Y
Brain Tumor Pathol; 2020 Apr; 37(2):50-59. PubMed ID: 32361941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
